Wayne Danson

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY.

New York State Society of Certified Public Accountants is a non-profit organization. It provides a membership program for certified public accountants that offers in-person and online networking opportunities, Continuing Professional Education courses and conferences, the CPA Journal, and other publications. The company was foudned in 1897 and is headquartered in New York, NY.

Badu Holdings, Inc. operates as a holding company. The company operates through its subsidiary Badu Networks, Inc., which designs, manufactures and sells products for the enterprise, telecommunication, commercial and small business markets that improve the performance of data delivery over wired and wireless networks. Its products and services are designed to address issues confronting networks. Badu Holdings was founded on October 24, 2018 and is headquartered in Irvine, CA.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

Part of EOM Pharmaceuticals Holdings, Inc., EOM Pharmaceuticals, Inc. is a privately held, clinical-stage company focused on developing novel drugs to improve the quality of life for patients with debilitating and sometimes deadly diseases. The company is based in Montvale, NJ. The company's mission is to pursue innovative approaches with small molecule therapeutics to address urgent and unmet medical needs. EOM's pipeline includes the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illnesses caused by intense inflammatory immune reactions, including COVID-19, influenza, and cancer cachexia. Additionally, EOM is working on an advanced formulation of EOM147, the first potential topically administered eye drop for treating retinal diseases. The company was founded by Shalom Z. Hirschman and Eli Goldberger, and Irach B. Taraporewala has been the CEO since 2020. EOM Pharmaceuticals was acquired by ImmunoCellular Therapeutics Ltd. on December 02, 2021.